Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
Completed
- Conditions
- Non Small Cell Lung Cancer
- Registration Number
- NCT01167972
- Lead Sponsor
- AstraZeneca
- Brief Summary
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.
- Detailed Description
MSD
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
- Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed
Read More
Exclusion Criteria
- Assessment of mutational status of EGFR is not done
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma At baseline
- Secondary Outcome Measures
Name Time Method Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx). 12 months / At each visit Describe the therapeutic management of patients with EGFR M +. 12 months / At each visit Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012 12 months / At each visit
Trial Locations
- Locations (1)
Research Site
🇫🇷Yerres, France